cas 854515-52-9|| where to buy 6-hydroxy-2-methylbenzofuran-3-carboxylic acid

Produktname:6-hydroxy-2-methylbenzofuran-3-carboxylic acid

IUPAC Name:6-hydroxy-2-methyl-1-benzofuran-3-carboxylic acid

Packungseinheit	Verfügbarer Vorrat	Preis($)
CM132795-100mg	in stock	ţǎŽ
CM132795-250mg	in stock	řŽǸ
CM132795-1g	in stock	ħřř
CM132795-5g	in stock	řħƴħ

Nur für den Einsatz in Forschung und Entwicklung..

Anfrage-Formular

Chemische Bezeichnung

CAS-Nummer

Menge*

Erforderliche Spezifikationen*
(Gehalt %, Materialqualität etc.)

Name des Ansprechpartners*

E-Mail des Ansprechpartners*

Meanwhile I'd like to create a registered account on CHEMENU.COM with the above email.

I'd like to receive emails related to products with similar structures to 854515-52-9 regularly via the above email.

Zusätzliche Hinweise

Verification code*

refresh

: CAS-Nr.:854515-52-9; Molekulare Formel:C10H8O4; Schmelzpunkt:-; SMILES-Code:CC1=C(C(O)=O)C2=C(O1)C=C(O)C=C2; Dichte:

: Katalognummer:CM132795; Molekulargewicht:192.17; Siedepunkt:235.838°C at 760 mmHg; Mdl-Nr.:MFCD12547297; Lagerung:Store at 2-8°C.

: Benzofurans; Benzofuran is an aromatic heterocyclic organic compound with the chemical formula C8H6O. It is a colorless oily liquid at room temperature with an aromatic odor. Benzofuran can be volatilized with water vapor and can be decomposed by potassium permanganate and other oxidants. It is an intermediate for the preparation of amiodarone and indene resin. Benzofuran derivatives are important pharmaceutical intermediates.; Benzofuran | C8H6O | CID 9223 -Chemenu; Benzofuran | C8H6O | CID 9223 |Where to Buy Benzofurans; Benzofuran is the heterocyclic compound consisting of fused benzene and furan rings. This colourless liquid is a component of coal tar.Benzofuran is extracted from coal tar. It is also obtained by dehydrogenation of 2-ethylphenol.

: Fruquintinib; November 08, 2023, FDA has approved FRUZAQLA(fruquintinib), an oral targeted therapy for adults with metastatic colorectal cancer (mCRC) who have been previously treated with fluoropyrimidine-, oxaliplatin-, and irinotecan-based chemotherapy, an anti-VEGF therapy, and, if RAS wild-type and medically appropriate, an anti-EGFR therapy.
FRUZAQLA is the first and only selective inhibitor of all three VEGF receptor kinases approved in the U.S. for previously treated mCRC regardless of biomarker status.